Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Equity Average (2016 - 2025)

Cytosorbents' Equity Average history spans 14 years, with the latest figure at $7.5 million for Q4 2025.

  • Quarterly results put Equity Average at $7.5 million for Q4 2025, down 39.06% from a year ago — trailing twelve months through Dec 2025 was $7.5 million (down 39.06% YoY), and the annual figure for FY2025 was $8.5 million, down 50.82%.
  • Equity Average for Q4 2025 was $7.5 million at Cytosorbents, down from $10.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $78.2 million in Q1 2021 to a low of $7.5 million in Q4 2025.
  • The 5-year median for Equity Average is $24.4 million (2023), against an average of $34.9 million.
  • The sharpest move saw Equity Average soared 532.69% in 2021, then tumbled 50.09% in 2023.
  • Year by year, Equity Average stood at $66.6 million in 2021, then plummeted by 44.05% to $37.3 million in 2022, then crashed by 43.25% to $21.1 million in 2023, then crashed by 42.09% to $12.2 million in 2024, then plummeted by 39.06% to $7.5 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $7.5 million, $10.3 million, and $13.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.